WO2009080933A1 - Procede et compositions pour la vaccination par voie cutanee - Google Patents
Procede et compositions pour la vaccination par voie cutanee Download PDFInfo
- Publication number
- WO2009080933A1 WO2009080933A1 PCT/FR2008/052198 FR2008052198W WO2009080933A1 WO 2009080933 A1 WO2009080933 A1 WO 2009080933A1 FR 2008052198 W FR2008052198 W FR 2008052198W WO 2009080933 A1 WO2009080933 A1 WO 2009080933A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- vaccine formulation
- antigen
- use according
- application
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 67
- 238000002649 immunization Methods 0.000 title abstract description 6
- 238000000034 method Methods 0.000 title description 21
- 238000009833 condensation Methods 0.000 claims abstract description 98
- 230000005494 condensation Effects 0.000 claims abstract description 98
- 102000036639 antigens Human genes 0.000 claims abstract description 96
- 108091007433 antigens Proteins 0.000 claims abstract description 96
- 239000000427 antigen Substances 0.000 claims abstract description 93
- 229960005486 vaccine Drugs 0.000 claims abstract description 61
- 230000028993 immune response Effects 0.000 claims abstract description 40
- 241000124008 Mammalia Species 0.000 claims abstract description 15
- 241000282414 Homo sapiens Species 0.000 claims abstract description 4
- 210000003491 skin Anatomy 0.000 claims description 140
- 238000009472 formulation Methods 0.000 claims description 53
- 239000002671 adjuvant Substances 0.000 claims description 45
- 230000006698 induction Effects 0.000 claims description 41
- 210000002615 epidermis Anatomy 0.000 claims description 33
- 150000001875 compounds Chemical class 0.000 claims description 24
- 230000036571 hydration Effects 0.000 claims description 22
- 238000006703 hydration reaction Methods 0.000 claims description 22
- 230000002500 effect on skin Effects 0.000 claims description 20
- 230000001070 adhesive effect Effects 0.000 claims description 16
- 239000000853 adhesive Substances 0.000 claims description 15
- 230000005875 antibody response Effects 0.000 claims description 13
- 238000002255 vaccination Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 230000035515 penetration Effects 0.000 claims description 8
- 238000011260 co-administration Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 230000035699 permeability Effects 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 238000005411 Van der Waals force Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 abstract description 6
- 230000003449 preventive effect Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 14
- 229940092253 ovalbumin Drugs 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 12
- 210000004443 dendritic cell Anatomy 0.000 description 12
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000009016 Cholera Toxin Human genes 0.000 description 10
- 108010049048 Cholera Toxin Proteins 0.000 description 10
- 108010058846 Ovalbumin Proteins 0.000 description 9
- 241000725643 Respiratory syncytial virus Species 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 230000002163 immunogen Effects 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 239000000560 biocompatible material Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- -1 polyethylenes Polymers 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 108010055044 Tetanus Toxin Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000005299 abrasion Methods 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 229940118376 tetanus toxin Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000001821 langerhans cell Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002390 adhesive tape Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000008350 antigen-specific antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000902095 Tiphys Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000036576 dermal application Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Surgical Instruments (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08864603.9A EP2217222B1 (fr) | 2007-12-03 | 2008-12-03 | Compositions pour la vaccination par voie cutanée |
JP2010536516A JP6017111B2 (ja) | 2007-12-03 | 2008-12-03 | 皮膚免疫付与のための方法および組成物 |
US12/745,673 US8968743B2 (en) | 2007-12-03 | 2008-12-03 | Method and compositions for cutaneous immunisation |
ES08864603T ES2570310T3 (es) | 2007-12-03 | 2008-12-03 | Composiciones para la vacunación por vía cutánea |
CN2008801188650A CN101883560A (zh) | 2007-12-03 | 2008-12-03 | 皮肤免疫用方法和组合物 |
CA2706363A CA2706363C (fr) | 2007-12-03 | 2008-12-03 | Procede et compositions pour la vaccination par voie cutanee |
AU2008339832A AU2008339832B2 (en) | 2007-12-03 | 2008-12-03 | Method and compositions for cutaneous immunisation |
IL205821A IL205821A (en) | 2007-12-03 | 2010-05-17 | Use of an immune formulation for the preparation of a pharmaceutical preparation for vaccination on the skin of mammals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0759505A FR2924350B1 (fr) | 2007-12-03 | 2007-12-03 | Procede et compositions pour la vaccination par voie cutanee |
FR0759505 | 2007-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009080933A1 true WO2009080933A1 (fr) | 2009-07-02 |
Family
ID=39537456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2008/052198 WO2009080933A1 (fr) | 2007-12-03 | 2008-12-03 | Procede et compositions pour la vaccination par voie cutanee |
Country Status (10)
Country | Link |
---|---|
US (1) | US8968743B2 (fr) |
EP (1) | EP2217222B1 (fr) |
JP (1) | JP6017111B2 (fr) |
KR (1) | KR101605694B1 (fr) |
CN (2) | CN104721815A (fr) |
CA (1) | CA2706363C (fr) |
ES (1) | ES2570310T3 (fr) |
FR (1) | FR2924350B1 (fr) |
IL (1) | IL205821A (fr) |
WO (1) | WO2009080933A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011128430A1 (fr) | 2010-04-16 | 2011-10-20 | Dbv Technologies | Procédé de vaccination |
US9539318B2 (en) | 2007-12-03 | 2017-01-10 | Dbv Technologies | Allergen desensitization method |
WO2020011746A1 (fr) | 2018-07-09 | 2020-01-16 | Dbv Technologies | Vaccination épicutanée optimisée |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2926466B1 (fr) * | 2008-01-23 | 2010-11-12 | Dbv Tech | Procede de fabrication de patchs par electrospray |
CN107320722A (zh) | 2009-09-07 | 2017-11-07 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
DK3562451T3 (da) * | 2016-12-30 | 2022-02-07 | Euromed Inc | Klæbeplaster med forbedret skillelagsystem |
CN112869865B (zh) * | 2021-01-11 | 2022-09-02 | 贵阳德漫多医疗科技有限公司 | 一种皮肤热剥脱装置 |
EP4201383A1 (fr) | 2021-12-21 | 2023-06-28 | DBV Technologies | Timbres améliorés et procédés d'administration d'une substance active pour la peau les utilisant |
WO2023066846A1 (fr) | 2021-10-18 | 2023-04-27 | Dbv Technologies | Timbres améliorés et procédés d'administration d'une substance active dans la peau au moyen de ceux-ci |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002071950A1 (fr) * | 2001-03-13 | 2002-09-19 | Dbv Technologies | Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, et utilisation |
WO2004030696A2 (fr) * | 2002-10-02 | 2004-04-15 | Nordic Vaccine Technology A/S | Composition vaccinale |
WO2007122226A2 (fr) * | 2006-04-26 | 2007-11-01 | Dbv Technologies | Timbre et utilisations de celui-ci |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB501873A (en) | 1937-04-20 | 1939-03-07 | Hermann Vollmer | New or improved means for carrying out medical tests |
US3212495A (en) | 1962-06-22 | 1965-10-19 | Hazleton Lab Inc | Sensitivity test patches |
BE642548A (fr) | 1963-01-19 | 1964-05-14 | ||
SE337223B (fr) | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
US3837340A (en) | 1971-10-20 | 1974-09-24 | Lilly Co Eli | Device for administering immunication against virus |
US3894531A (en) | 1974-04-12 | 1975-07-15 | Jr Milton A Saunders | Skin patch test device with peelable label |
US4450844A (en) | 1981-11-23 | 1984-05-29 | Hill Top Research, Inc. | Patch system for use on the skin |
US4435180A (en) | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
AU590711B2 (en) | 1982-10-13 | 1989-11-16 | Biowhittaker, Inc. | Stable allergenic extracts and methods |
SE8404895L (sv) | 1984-10-01 | 1986-03-17 | Torkel Ingemar Fischer | Medel for en overkenslighetstest |
US4743249A (en) | 1986-02-14 | 1988-05-10 | Ciba-Geigy Corp. | Dermal and transdermal patches having a discontinuous pattern adhesive layer |
US4781705A (en) | 1987-06-16 | 1988-11-01 | Zyton Inc. | Mineral applicator |
US4788971A (en) | 1987-07-13 | 1988-12-06 | Hill Top Research, Inc. | Patch system for use on the skin |
US4821733A (en) | 1987-08-18 | 1989-04-18 | Dermal Systems International | Transdermal detection system |
US5438984A (en) | 1988-09-08 | 1995-08-08 | Sudor Partners | Apparatus and method for the collection of analytes on a dermal patch |
US5037587A (en) | 1989-07-17 | 1991-08-06 | Mitsui Toatsu Chemicals, Inc. | Preparation process of polyimide film |
US5236455A (en) | 1992-02-10 | 1993-08-17 | Wilk Peter J | Tympanic patch, applicator, and related method |
JPH06238008A (ja) | 1993-02-15 | 1994-08-30 | Yuutoku Yakuhin Kogyo Kk | パッチテスト用具 |
AU5543196A (en) | 1995-04-12 | 1996-10-30 | Robert B. Hopp | Skin patch for use in contact immunotherapy |
US6093419A (en) | 1995-06-07 | 2000-07-25 | Lectec Corporation | Compliance verification method and device in compulsory drug administration |
US5827530A (en) | 1996-02-05 | 1998-10-27 | Reed, Jr.; Fred Dewitt | Fillable patch for dermal or transdermal delivery |
US5827608A (en) | 1996-10-28 | 1998-10-27 | Minnesota Mining And Manufacturing Company | Method of forming a thermoplastic layer on a flexible two-dimensional substrate and powder for preparing same |
US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
DE29621365U1 (de) | 1996-12-11 | 1997-02-27 | Lohmann Gmbh & Co Kg | Epikutan-Testpflaster |
US5827068A (en) * | 1996-12-31 | 1998-10-27 | Michelson Packaging Co. | Fruit packaging tray usable with a denesting apparatus |
US20020102291A1 (en) | 1997-12-15 | 2002-08-01 | Noven Pharmaceuticals, Inc. | Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
US6210705B1 (en) | 1997-12-15 | 2001-04-03 | Noven Pharmaceuticals, Nc. | Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate |
EP1356821B1 (fr) | 1998-02-25 | 2007-06-20 | THE GOVERNMENT OF THE UNITED STATES, as represented by THE SECRETARY OF THE ARMY | Utilisation d'amplificateurs de pénétration de la peau et d'agents de rupture de barrière afin d'augmenter la réponse immune transcutanée |
FR2781670B1 (fr) | 1998-07-30 | 2001-09-07 | Oreal | Patch cosmetique ou pharmaceutique et son conditionnement |
JP2987702B1 (ja) | 1998-09-07 | 1999-12-06 | 岩手新浄農業協同組合 | 粉末青果物の製造方法 |
US6159497A (en) | 1998-10-30 | 2000-12-12 | Noven Pharmaceuticals, Inc. | Patch applicator |
WO2000043058A1 (fr) | 1999-01-22 | 2000-07-27 | Powderject Research Limited | Methode favorisant l'administration transdermique sans aiguille de medicaments en poudre |
SI1031346T1 (en) | 1999-01-27 | 2002-08-31 | Idea Ag | Noninvasive vaccination through the skin |
AU4188100A (en) * | 1999-04-08 | 2000-11-14 | Gregory M. Glenn | Dry formulation for transcutaneous immunization |
US6316598B1 (en) | 1999-09-13 | 2001-11-13 | Keraplast Technologies, Ltd. | Water absorbent keratin and gel formed therefrom |
AU784593B2 (en) | 2000-01-06 | 2006-05-11 | Marantech Holding, Llc | Compositions and methods for facilitating skin growth and managing skin conditions |
WO2001053331A2 (fr) | 2000-01-24 | 2001-07-26 | Adherex Technologies, Inc. | Modulateurs peptidomimetiques de l'adhesion cellulaire |
US20020151487A1 (en) | 2000-08-31 | 2002-10-17 | Loyola University Chicago | Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway |
RU2277390C2 (ru) | 2000-10-13 | 2006-06-10 | Алза Корпорейшн | Аппликатор для силового воздействия комплектом микроножей |
WO2002076379A2 (fr) | 2000-11-16 | 2002-10-03 | Chris Lipper | Tatouages medicamentes |
PT1372708E (pt) * | 2001-02-13 | 2008-09-29 | Us Gov Sec Army | Vacina para imunização transcutânea |
JP2004525921A (ja) | 2001-03-19 | 2004-08-26 | イオマイ コーポレイシヨン | 経皮免疫用パッチ |
US20050074462A1 (en) | 2001-05-23 | 2005-04-07 | Duotol Ab | Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof |
US7195774B2 (en) | 2001-08-29 | 2007-03-27 | Carvalho Ricardo Azevedo Ponte | Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues |
US20040137004A1 (en) | 2002-03-19 | 2004-07-15 | Glenn Gregory M | Patch for transcutaneous immunization |
US20060147509A1 (en) | 2002-10-02 | 2006-07-06 | Kirkby Nikolai S | Composition for vaccination |
US20040111071A1 (en) | 2002-12-09 | 2004-06-10 | Jeffrey Lewis Powers | Portable device for dispensing hand treatments |
FR2866553B1 (fr) | 2004-02-19 | 2006-06-09 | Dbv Tech | Nouveau type de patch |
WO2006007366A2 (fr) | 2004-06-15 | 2006-01-19 | Iomai Corporation | Immunisation transcutanee utilisant des proteines de fusion lt-sta |
JP5186678B2 (ja) * | 2005-10-13 | 2013-04-17 | 財団法人ヒューマンサイエンス振興財団 | 経皮抗原投与のための抗原キット |
-
2007
- 2007-12-03 FR FR0759505A patent/FR2924350B1/fr active Active
-
2008
- 2008-12-03 WO PCT/FR2008/052198 patent/WO2009080933A1/fr active Application Filing
- 2008-12-03 KR KR1020107011702A patent/KR101605694B1/ko active IP Right Grant
- 2008-12-03 CN CN201510087956.4A patent/CN104721815A/zh active Pending
- 2008-12-03 US US12/745,673 patent/US8968743B2/en active Active
- 2008-12-03 ES ES08864603T patent/ES2570310T3/es active Active
- 2008-12-03 EP EP08864603.9A patent/EP2217222B1/fr active Active
- 2008-12-03 JP JP2010536516A patent/JP6017111B2/ja active Active
- 2008-12-03 CA CA2706363A patent/CA2706363C/fr active Active
- 2008-12-03 CN CN2008801188650A patent/CN101883560A/zh active Pending
-
2010
- 2010-05-17 IL IL205821A patent/IL205821A/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002071950A1 (fr) * | 2001-03-13 | 2002-09-19 | Dbv Technologies | Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, et utilisation |
WO2004030696A2 (fr) * | 2002-10-02 | 2004-04-15 | Nordic Vaccine Technology A/S | Composition vaccinale |
WO2007122226A2 (fr) * | 2006-04-26 | 2007-11-01 | Dbv Technologies | Timbre et utilisations de celui-ci |
Non-Patent Citations (1)
Title |
---|
ANTHONI MINNA ET AL: "Smad3 signal transducer regulates skin inflammation and specific IgE response in murine model of atopic dermatitis.", THE JOURNAL OF INVESTIGATIVE DERMATOLOGY AUG 2007, vol. 127, no. 8, August 2007 (2007-08-01), pages 1923 - 1929, XP002487281, ISSN: 1523-1747 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10022439B2 (en) | 2007-12-03 | 2018-07-17 | Dbv Technologies | Allergen desensitization method |
US11931411B2 (en) | 2007-12-03 | 2024-03-19 | Dbv Technologies | Allergen desensitization method |
US11202826B2 (en) | 2007-12-03 | 2021-12-21 | Dbv Technologies | Allergen desensitization method |
US10758610B2 (en) | 2007-12-03 | 2020-09-01 | Dbv Technologies | Allergen desensitization method |
US10272151B2 (en) | 2007-12-03 | 2019-04-30 | Dbv Technologies | Allergen desensitization method |
US9539318B2 (en) | 2007-12-03 | 2017-01-10 | Dbv Technologies | Allergen desensitization method |
CN107441483A (zh) * | 2010-04-16 | 2017-12-08 | Dbv技术公司 | 免疫接种的方法 |
WO2011128430A1 (fr) | 2010-04-16 | 2011-10-20 | Dbv Technologies | Procédé de vaccination |
AU2011239941B2 (en) * | 2010-04-16 | 2015-07-16 | Dbv Technologies | Method of vaccination |
JP2013525295A (ja) * | 2010-04-16 | 2013-06-20 | デベヴェ テクノロジーズ | ワクチン接種方法 |
CN103096919A (zh) * | 2010-04-16 | 2013-05-08 | Dbv技术公司 | 免疫接种的方法 |
US20130039958A1 (en) * | 2010-04-16 | 2013-02-14 | Dbv Technologies | Method of vaccination |
WO2020011746A1 (fr) | 2018-07-09 | 2020-01-16 | Dbv Technologies | Vaccination épicutanée optimisée |
Also Published As
Publication number | Publication date |
---|---|
KR101605694B1 (ko) | 2016-03-24 |
CN101883560A (zh) | 2010-11-10 |
IL205821A (en) | 2017-03-30 |
JP2011505412A (ja) | 2011-02-24 |
ES2570310T3 (es) | 2016-05-17 |
FR2924350A1 (fr) | 2009-06-05 |
KR20100093536A (ko) | 2010-08-25 |
JP6017111B2 (ja) | 2016-10-26 |
EP2217222A1 (fr) | 2010-08-18 |
AU2008339832A1 (en) | 2009-07-02 |
EP2217222B1 (fr) | 2016-02-17 |
FR2924350B1 (fr) | 2010-08-13 |
US20100310596A1 (en) | 2010-12-09 |
CA2706363C (fr) | 2016-09-13 |
CN104721815A (zh) | 2015-06-24 |
US8968743B2 (en) | 2015-03-03 |
CA2706363A1 (fr) | 2009-07-02 |
IL205821A0 (en) | 2010-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2217222B1 (fr) | Compositions pour la vaccination par voie cutanée | |
EP2214704B1 (fr) | Methode de desensibilisation aux allergenes | |
JP4875799B2 (ja) | Adp−リボシル化外毒素により誘引される経皮免疫応答を促進するための皮膚浸透性エンハンサーおよびバリア崩壊剤の使用 | |
US20090136480A1 (en) | Transcutaneous immunostimulation | |
Courtenay et al. | Novel hydrogel-forming microneedle array for intradermal vaccination in mice using ovalbumin as a model protein antigen | |
JP2001514212A (ja) | 免疫原経皮投与のための2相脂質小胞組成物 | |
EP1381381A1 (fr) | Timbre d'immunisation transcutanee | |
Azegami et al. | Nanogel-based nasal vaccines for infectious and lifestyle-related diseases | |
Yu et al. | Microneedle-based two-step transdermal delivery of Langerhans cell-targeting immunoliposomes induces a Th1-biased immune response | |
EP2205228A2 (fr) | Patch pour application cutanée contenant une poudre hydrophile | |
US20100136092A1 (en) | Transdermal immune preparation, method for production of the same, and transdermal immunization method using the same | |
JP2012090767A (ja) | ワクチン抗原表皮デリバリー用溶解性3層マイクロニードル・アレイ・パッチ | |
WO2018185113A1 (fr) | Préparation pharmaceutique pour administration dermique | |
WO2015056710A1 (fr) | Préparation immune transdermique | |
FR2487201A2 (fr) | Preparation lymphocytaires applicables en therapeutique humaine, procede d'obtention et applications | |
Sawicka | Development of a Novel Immunization Platform | |
CN101304735A (zh) | 用于挥发性和/或热不稳定的物质的经皮治疗体系 | |
Sevast'Yanov et al. | Transdermal insulin delivery systems | |
JP2010059140A (ja) | 経皮免疫製剤及びその製造方法 | |
IL180509A (en) | Skin Transmission Transmission System | |
AU2002306740A1 (en) | Patch for transcutaneous immunization | |
MXPA00002036A (en) | Biphasic lipid vesicle composition for transdermal administration of an immunogen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880118865.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08864603 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008339832 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 205821 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2706363 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008864603 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107011702 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12745673 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2008339832 Country of ref document: AU Date of ref document: 20081203 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010536516 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1431/MUMNP/2010 Country of ref document: IN |